BR112019003722A2 - terapias de combinação para o tratamento de carcinoma hepatocelular - Google Patents

terapias de combinação para o tratamento de carcinoma hepatocelular

Info

Publication number
BR112019003722A2
BR112019003722A2 BR112019003722A BR112019003722A BR112019003722A2 BR 112019003722 A2 BR112019003722 A2 BR 112019003722A2 BR 112019003722 A BR112019003722 A BR 112019003722A BR 112019003722 A BR112019003722 A BR 112019003722A BR 112019003722 A2 BR112019003722 A2 BR 112019003722A2
Authority
BR
Brazil
Prior art keywords
treatment
hepatocellular carcinoma
combination therapies
inhibitor
combination
Prior art date
Application number
BR112019003722A
Other languages
English (en)
Inventor
Selvaraj Anand
Smith Peter
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112019003722A2 publication Critical patent/BR112019003722A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

é fornecida aqui uma terapia de combinação útil para o tratamento de carcinoma hepatocelular e/ou colangiocarcinoma intra-hepático. a combinação compreende um inibidor fgfr4 e um inibidor cdk 4/6.
BR112019003722A 2016-08-23 2017-08-23 terapias de combinação para o tratamento de carcinoma hepatocelular BR112019003722A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
BR112019003722A2 true BR112019003722A2 (pt) 2019-05-28

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003722A BR112019003722A2 (pt) 2016-08-23 2017-08-23 terapias de combinação para o tratamento de carcinoma hepatocelular

Country Status (14)

Country Link
US (1) US20190175598A1 (pt)
EP (1) EP3503923B1 (pt)
JP (1) JP7190425B2 (pt)
KR (1) KR102466192B1 (pt)
CN (1) CN109803684B (pt)
AU (1) AU2017315357B2 (pt)
BR (1) BR112019003722A2 (pt)
CA (1) CA3034875C (pt)
ES (1) ES2966469T3 (pt)
IL (1) IL264950B2 (pt)
MX (1) MX2019002115A (pt)
RU (1) RU2769251C2 (pt)
SG (1) SG11201901472TA (pt)
WO (1) WO2018039324A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205821B2 (en) 2018-01-08 2024-07-18 G1 Therapeutics, Inc. G1T38 superior dosage regimes
AU2019269159A1 (en) 2018-05-14 2020-11-19 Pfizer Inc. Oral solution formulation
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
MXPA02007005A (es) 2000-01-18 2004-09-06 Aventis Pharma Inc Pseudopolimorfo de (-) -cis-2 -(2-clorofenil) -5, 7-dihidorxi -8[4r-(3s-hidroxi -1-meitl) piperidinil] -4h-1-benzopiran -4-ona.
JP2003520798A (ja) 2000-01-18 2003-07-08 アベンテイス・フアーマシユーチカルズ・インコーポレーテツド （−）−シス−２−（２−クロロフェニル）−５，７−ジヒドロキシ−８［４ｒ−（３ｓ−ヒドロキシ−１−メチル）ピペリジニル］−４ｈ−１−ベンゾピラン−４−オンのエタノール溶媒化合物
US20050004007A1 (en) 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
BRPI0307057B8 (pt) 2002-01-22 2021-05-25 Warner Lambert Co compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
AU2006207322A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EP2043635A2 (en) 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
JP2009544602A (ja) 2006-07-21 2009-12-17 アステックス・セラピューティクス・リミテッド サイクリン依存性キナーゼ阻害剤の医学的使用
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
GEP20125502B (en) * 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
RU2589696C2 (ru) * 2010-04-13 2016-07-10 Новартис Аг КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА
EP3381920B1 (en) 2010-10-25 2019-03-27 G1 Therapeutics, Inc. Cdk inhibitors
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
WO2013006368A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
SI2968290T1 (sl) 2013-03-15 2020-02-28 G1 Therapeutics, Inc., Prehodna zaščita normalnih celic med kemoterapijo
EP4005573A1 (en) * 2013-08-14 2022-06-01 Novartis AG Combination therapy for the treatment of cancer
BR112016008110B1 (pt) 2013-10-18 2019-07-02 Eisai R&D Management Co., Ltd. Composto inibidor de pirimidina fgfr4, composição farmacêutica compreendendo dito compoto e usos terapêuticos destes
WO2016025650A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
ES2864712T3 (es) * 2015-04-14 2021-10-14 Eisai R&D Man Co Ltd Compuesto inhibidor de FGFR4 cristalino y usos del mismo

Also Published As

Publication number Publication date
JP7190425B2 (ja) 2022-12-15
CA3034875A1 (en) 2018-03-01
RU2769251C2 (ru) 2022-03-29
SG11201901472TA (en) 2019-03-28
KR102466192B1 (ko) 2022-11-14
ES2966469T3 (es) 2024-04-22
CN109803684B (zh) 2022-08-23
KR20190040996A (ko) 2019-04-19
AU2017315357B2 (en) 2022-12-01
IL264950B1 (en) 2023-09-01
JP2019528302A (ja) 2019-10-10
RU2019108259A3 (pt) 2020-11-24
WO2018039324A1 (en) 2018-03-01
AU2017315357A1 (en) 2019-02-28
EP3503923B1 (en) 2023-10-04
IL264950A (en) 2019-05-30
CN109803684A (zh) 2019-05-24
RU2019108259A (ru) 2020-09-25
MX2019002115A (es) 2019-07-08
EP3503923A1 (en) 2019-07-03
CA3034875C (en) 2024-05-28
US20190175598A1 (en) 2019-06-13
IL264950B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
BR112017007782A2 (pt) agentes imunorreguladores
BR112017008809A2 (pt) agentes imunorreguladores
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
CY1120354T1 (el) Αναστολεις ακυλοτρανσφερασης της διακυλογλυκερολης 2 για χρηση στη θεραπεια μεταβολικων και συγγενων διαταραχων
BR112019003722A2 (pt) terapias de combinação para o tratamento de carcinoma hepatocelular
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
IL276398A (en) Combined treatment for mastocytosis
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
WO2015173633A3 (en) Hdl therapy markers
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112019019261A2 (pt) Terapias de combinação para o tratamento de câncer de mama
CL2021001433A1 (es) Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
BR112017013982A2 (pt) fármaco de combinação
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
AR108148A1 (es) Métodos para recubrir superficies de empaque con compuestos de benzoxaborol para preservar la frescura de los alimentos
IL281244A (en) Therapeutic combination for the treatment of liver diseases
BR112018013928A2 (pt) composições terapêuticas e métodos para tratamento da hepatite b
SG11202007873VA (en) Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
IL274747A (en) FXR agonists for the treatment of liver diseases
WO2016046414A3 (en) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements